Gerald W. St. Peter

Eyevance Pharmaceuticals Holdings, Inc operates as a holding company through its subsidiaries develops ophthalmic therapies for the ocular surface and anterior segment. The company was founded by Jerry St. Peter and Jason Werner in September 2017 and is headquartered in Fort Worth, TX.

InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy.

SightStream Biotherapeutics develops cytoprotectives to reverse ocular cell death. The company is based in Dallas-Fort Worth, TX. The company was founded by Jack Jiagang Zhao.

InFocus Capital Partners (InFocus Capital Partners) is a venture capital firm founded in 2016 by Rob Rothman and Ron Weiss. The firm is headquartered in Jericho, New York.

Northwell Health, Inc. engages in the provision of medical and healthcare services. It offers several long-term care facilities, rehabilitation services, outpatient surgery centers, home care, hospice, diagnostic laboratory facilities, and emergency medical services. The company was founded in 1997 and is headquartered in New Hyde Park, NY.

Stuart Therapeutics LLC, founded in 2017, is a company based in Stuart, FL that specializes in the development of ECM-targeting therapeutics for disease treatment. Stuart Therapeutics has conducted extensive research in a variety of anterior and posterior segment ophthalmic disease indications, demonstrating rapid effects in treated tissues. The company's patented platform technology, PolyCol™, is a portfolio of synthesized collagen mimetic peptides designed to repair disease or injury-damaged helical collagen structures. This repair results in a restoration of homeostatic cell signaling, positively affecting cell growth and proliferation while reducing inflammation. The company was founded in 2018 by Eric Schlumpf, who has been the CEO since then.